shutterstock_1953872293_marlon_trottmann
Marlon Trottmann / Shutterstock.com
18 May 2023Big PharmaMuireann Bolger

FTC sues to bar Amgen from major IP $28bn acquisition

The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
13 December 2022   Two rivals withdrew from acquisition process| Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.

More on this story

Americas
13 December 2022   Two rivals withdrew from acquisition process| Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.

More on this story

Americas
13 December 2022   Two rivals withdrew from acquisition process| Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.